Theravance Biopharma (TBPH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TBPH Theravance Biopharma

Watchlist

8.280
+0.040+0.49%

Close Nov 1 16:00 ET

8.280
0.0000.00%

Post 20:02 ET

405.07MMarket Cap-8715P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
PR NewswireOct 24 06:00 ET
Theravance Biopharma's Revefenacin Improves Bronchodilation in Published Study
TipRanksOct 18 09:07 ET
Express News | Theravance Publishes Sub-Study 12-Week, Randomized, Registrational Revefenacin Phase 3 Trials For YUPELRI
BenzingaOct 18 09:04 ET
Express News | Theravance Announces Publication of Yupelri® (Revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
ReutersOct 18 09:00 ET
Express News | Theravance Biopharma Inc Says on Sept 18, Co's Units, Mylan Entered Into Settlement Agreement With Qilu Pharmaceutical - SEC Filing
ReutersSep 23 06:09 ET
Unveiling 4 Analyst Insights On Theravance Biopharma
BenzingaSep 16 08:00 ET

Comments

Moomoo AI

Feb 5 08:17

Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.

Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To Profit

Moomoo AI

Jan 9 06:20

Theravance Biopharma's high P/S ratio is alarming considering its unimpressive revenue predictions. Investors seem hopeful for a business turnaround, but analysts lack confidence. The anticipated revenue growth could pressure the share price.

Investor Optimism Abounds Theravance Biopharma, Inc. (NASDAQ:TBPH) But Growth Is Lacking

Moomoo AI

Dec 21, 2023 18:34

The appointment of Jeremy Grant and the cooperation with Irenic are seen as positive steps towards strengthening Theravance's position. Irenic supports Theravance's potential to successfully complete the Phase 3 trial of ampreloxetine and deliver enhanced value to shareholders.

Press Release: Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Trytosaveabit

Nov 13, 2023 07:25

Update

$Theravance Biopharma (TBPH.US)$ Viatris And Theravance Biopharma Announce Top-Line Results From Yupelri Phase III Trial In China For The Treatment Of Chronic Obstructive Pulmonary Disease
Moomoo 24/7· 3 mins ago

Moomoo AI

Nov 12, 2023 06:46

The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.

Bearish: Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenue and EPS Estimates

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

TBPH Theravance Biopharma

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target